#Japan #Tokyo #Space Seed Holdings #Regenesome #Epigenetic Clock

Regenesome's Innovative Epigenetic Clock Patent

Regenesome Inc., a subsidiary of Space Seed Holdings, headquartered in Minato, Tokyo, has made significant progress in the realm of biotechnology by developing a new algorithm that accurately predicts biological age using biological samples like human saliva. The company has announced that it has formally applied for a patent on this groundbreaking technology, which aims to provide high precision and deeper interpretability in assessing aging states.

This innovative technology utilizes a new implementation of the "epigenetic clock," which leverages DNA methylation information. A key feature of Regenesome's method is its ability to adapt to non-linear aging patterns, setting it apart from traditional linear models. Utilizing a machine learning approach known as Lazy Learning, the algorithm estimates the age of an individual based on historical similar cases. This advancement not only demonstrates the capability of Regenesome’s technology but also sheds light on the potential for more nuanced understandings of the aging process.

Further enhancing the accuracy of biological age estimations, Regenesome has integrated feature selection based on correlation coefficients and optimized marker sets. This combination allows for high-precision predictions even from limited datasets. In validation tests using public databases, the new technology achieved a remarkable correlation coefficient of 0.90, affirming its effectiveness.

Regenesome's development is grounded in its mission of "social implementation of regenerative medical technologies and extending healthy life spans." The company is exploring effortless screening technologies using saliva and blood samples. Furthermore, it envisions collaborations with intervention-based healthcare products, thereby positioning itself at the forefront of a healthcare revolution that addresses aging concerns.

About Regenesome Inc.

Regenesome focuses on creating innovative solutions for aging suppression and regenerative medicine by utilizing nanoparticles such as exosomes. The company deeply analyzes the exosomes produced by various cells and employs molecular biology to design these nanoparticles, investigating their functionalities within biological systems. Through its pioneering efforts, Regenesome aspires to develop medical technologies deploying nanoparticles and propose novel solutions in the field of space medicine, contributing to both extending healthy lifespans and facilitating humanity's advancement into space.

For more details about Regenesome, visit Regenesome Official Site.

About Space Seed Holdings

Space Seed Holdings carries a visionary mission of turning science fiction into reality through investment, research, and the creation of ventures in the deep tech space. It is actively involved in the Fermentation and Longevity Fund program, aimed at implementing fermentation and longevity technologies in society. The company is dedicated to solving social challenges through business innovation, setting an ambitious goal to equip humanity with necessary technologies for living in outer space by 2040, in collaboration with various stakeholders.

To learn more about Space Seed Holdings, visit Space Seed Holdings Official Site.